= Open Trials for patients to fill in.

= On Going Trials.

= Finished Trials.

= Trial Information.

Open and On Going Clinical Trials

Study Year Pathology Sponsor Info

Trials Finished

Study Year Pathology Sponsor Info
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF). 2018 Chronic Heart Failure Boehringer Ingelheim International GmbH
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF). 2018 Chronic Heart Failure Boehringer Ingelheim International GmbH
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexat 2018 Rheumatoid Arthritis R-Pharm
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF) 2017 Chronic Heart Failure Amgen Inc.
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cc-220 in subjects with active systemic lupus erythematosus 2017 Systemic Lupus Erythematosus Celgene International II Sàrl
Study to Evaluate the effect of Dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction 2017 Chronic Heart Failure AstraZeneca AB
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial S 2017 Axial Spondyloarthritis Eli Lilly and Company
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive 2017 Psoriatic Arhritis Eli Lilly and Company
A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis 2017 Ulcerative Colitis Takeda Development Center Americas Inc.
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients with Nonradiographic Axial Spondyloarthritis 2016 Axial Spondyloarthritis Eli Lilly and Company
Ver más estudios